October 15, 2003

Skinvisible Launches Its Proprietary Polymer Technology and Related Formulations In European Market

LAS VEGAS, Oct 15, 2003 /PRNewswire-FirstCall via COMTEX/ --

Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website: www.skinvisible.com ) announced today that it has signed an Agreement with European Launch Pad ('ELP') of Switzerland for the purpose of launching its patent-pending polymer technology and related formulations within the European marketplace. ELP offers an established program by which U.S. companies with proprietary technology and products can expand into the European market through sub-license agreements with joint venture partners they introduce.

Terms of the Agreement require Skinvisible to pay fees to ELP based on its successful completion of various launch-related milestones. Such fees will be paid through the issuance of Skinvisible shares to ELP. Skinvisible will earn income from the sale of licenses and through ongoing royalties for its product formulas.

The ELP Agreement is exclusive of the existing marketing program Skinvisible presently has with RAHN (UK) Limited with offices in Switzerland and the UK.

Headquartered in Las Vegas, Nevada, Skinvisible Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., develops topical polymer-based delivery systems and technologies. Aligned with its research and development focus, Skinvisible's primary marketing objectives are to license its technologies and/or sell its polymer delivery systems to established brand manufacturers and providers of topical prescription, OTC, cosmetic and skincare products.

This press release contains 'forward looking'statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-QSB for the quarter ended June 30, 2003.

For Further Information Contact Mr. T. Howlett, President ~ Phone (702) 433-7154 / Fax (702) 433-7192 / Email: terry@skinvisible.com

Press Release Index

New Press Release Alerts:

If you are interested in receiving corporate and new product development news from Skinvisible, simply enter your email address below.